Gene therapy can help reduce joint bleeds in hemophilia B: New data
Beqvez (fidanacogene elaparvovec-dzkt), a discontinued gene therapy for hemophilia B, was shown to help reduce joint bleeding in…
Articles by Marisa Wexler, MS
Geneventiv notes FDA ‘positive’ feedback on hemophilia A therapy
Geneventiv Therapeutics said it had a “positive and constructive” meeting with the U.S. Food and Drug Administration (FDA) on…
Biomarin plans to sell rights to hemophilia A therapy Roctavian
Biomarin Pharmaceutical is looking to sell off rights to Roctavian (valoctocogene roxaparvovec-rvox), its approved gene therapy for…
Hemophilia affects intimacy, but patients stay quiet
Hemophilia has a substantial impact on sexual function and well-being for many men with the disease, but they rarely…
New FIX versions may be used to create hemophilia B treatments
Researchers have developed new versions of clotting factor IX (FIX) that may be used to create personalized treatments for people with hemophilia…
Hemophilia lab test update ensures accuracy with new treatments
Precision Biologic has announced an update of its Cryocheck Chromogenic Factor VIII assay, a test used to help diagnose…
Study: 4 of 5 hemophilia centers in Italy lack pregnancy protocols
Special care is needed to manage pregnancy and childbirth for women who have or are carriers of hemophilia, yet…
Hip replacement can benefit hemophilia patients, but risks exist
Total hip replacement surgery for hemophilia patients is usually successful in creating a more functional joint, according to a…
FDA expands Alhemo approval to help more people with hemophilia
The U.S. Food and Drug Administration (FDA) has expanded its approval of Alhemo (concizumab-mtci), a daily therapy injected under…
First-in-human trial of hemophilia B treatment BE-101 starts dosing
For the first time, as part of a U.S. clinical trial, the cell therapy BE-101 has been administered to someone…